Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Nkarta Inc

NKTX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.33

▲ +1.30%

Market Cap $166.89M · Vol 108.60K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$166.89M

Micro Cap

Div Yield

N/A

EPS Growth

-18.24%

YoY

RSI (14)

53.47

Momentum

Beta

0.96

vs Market

52W High

$3.72

37.28% below

52W Low

$1.71

36.66% above

Volume

108.60K

Avg 205.85K

P/B

0.42

Price-to-book

ROE

N/A

Return on equity

Free Float

94.95%

Public shares

Shariah Compliance8 STANDARDS

✗ Nkarta Inc (NKTX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NKTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.32%

-12.08%

-17.08%

+18.27%

YTD

+25.95%

+5.91%

+17.68%

-93.81%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-104,084,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-22.99% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.42
P/FCF	N/A
EPS Growth	-18.24%
Outstanding Shares	71.62M

Technical Indicators

50-Day SMA	$2.62
200-Day SMA	$2.39
RSI (14)	53.47
Beta	0.96
52-Week High	$3.72
52-Week Low	$1.71

Volume Today	108.60K
Avg Daily Volume (30D)	205.85K
Relative Volume	0.53x
Volatility (10D)	56.36
Volatility (30D)	70.42
Free Float	94.95%

Analyst Consensus

BUY

Current Price $2.33

Mean Target $11.20

52W Low$1.71 52W High$3.72

Current

Target

$1.71 $3.72

Current Analyst target

+380.69% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00JXHS9H6

ISINUS65487U1088

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 8, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.